Peng T, Lu J, Zheng X, Zeng C, He Y
Respir Res. 2025; 26(1):99.
PMID: 40075458
PMC: 11905457.
DOI: 10.1186/s12931-025-03163-3.
Shi X, Ma X, Wang H, He X, Fan H, Mao Y
Sci Rep. 2025; 15(1):5410.
PMID: 39948088
PMC: 11825724.
DOI: 10.1038/s41598-025-89130-w.
Wang X, Yang L, Gu B, Su D
Pulm Circ. 2024; 14(4):e70033.
PMID: 39720342
PMC: 11667098.
DOI: 10.1002/pul2.70033.
Rodolfi S, Ong V, Denton C
Int J Cardiol Congenit Heart Dis. 2024; 16:100513.
PMID: 39712533
PMC: 11657338.
DOI: 10.1016/j.ijcchd.2024.100513.
Ding Z, Qi F, Liu L, Wang Z, Zhang N, Lyu X
Front Immunol. 2024; 15:1374100.
PMID: 39364410
PMC: 11446868.
DOI: 10.3389/fimmu.2024.1374100.
Prevalence, Predictors, and Outcomes of Pulmonary Hypertension in Patients with Lupus Nephritis.
Chen S, Guo J, Huang X, He W, Yu X, Xia X
Medicina (Kaunas). 2024; 60(6).
PMID: 38929605
PMC: 11205415.
DOI: 10.3390/medicina60060988.
The prognosis and management of reclassified systemic lupus erythematosus associated pulmonary arterial hypertension according to 2022 ESC/ERS guidelines.
Li Y, Qian J, Dong X, Zhao J, Wang Q, Wang Y
Arthritis Res Ther. 2024; 26(1):109.
PMID: 38802957
PMC: 11129383.
DOI: 10.1186/s13075-024-03338-1.
Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu S, Kilickiran Avci B, Hatemi G
Intern Emerg Med. 2024; 19(3):731-743.
PMID: 38378970
PMC: 11039558.
DOI: 10.1007/s11739-024-03539-1.
Risk Factors for Pulmonary Arterial Hypertension in Patients With Systemic Lupus Erythematosus: A Systematic Review and Expert Consensus.
Atsumi T, Bae S, Gu H, Huang W, Li M, Nikpour M
ACR Open Rheumatol. 2023; 5(12):663-676.
PMID: 37794618
PMC: 10716809.
DOI: 10.1002/acr2.11611.
Survival and prognosis analysis of systemic lupus erythematosus patients with pulmonary hypertension: A systematic review and meta-analysis.
Yang J, Zhou F, Zhou X, Sun Y, Lun X, Cao J
Medicine (Baltimore). 2023; 102(36):e34947.
PMID: 37682181
PMC: 10489205.
DOI: 10.1097/MD.0000000000034947.
Retrospective cohort study of pulmonary arterial hypertension associated with connective tissue disease effect on patients' prognosis.
Huang J, An Q, Shi H, Li C, Zhang W, Wang L
Clin Rheumatol. 2023; 42(11):3131-3142.
PMID: 37382842
DOI: 10.1007/s10067-023-06667-9.
Mean pulmonary artery pressure estimated by echocardiogram rapidly exceeds 20 mmHg from the normal range in patients with connective tissue disease.
Orihara Y, Asakura M, Min K, Matsumoto Y, Sunayama I, Nishimura K
Heart Vessels. 2023; 38(9):1172-1180.
PMID: 37074476
DOI: 10.1007/s00380-023-02267-4.
Systemic Lupus Erythematosus and Pulmonary Hypertension.
Parperis K, Velidakis N, Khattab E, Gkougkoudi E, Kadoglou N
Int J Mol Sci. 2023; 24(6).
PMID: 36982160
PMC: 10049584.
DOI: 10.3390/ijms24065085.
Clinical characteristics and survival analysis of class I pulmonary arterial hypertension.
Zheng L, Yang Y, Zhao W, Yang H, Zhan H, Zhao Y
Am J Transl Res. 2023; 15(2):1476-1484.
PMID: 36915738
PMC: 10006787.
10-year survival of pulmonary arterial hypertension associated with connective tissue disease: insights from a multicentre PAH registry.
Chen X, Quan R, Qian Y, Yang Z, Yu Z, Zhang C
Rheumatology (Oxford). 2023; 62(11):3555-3564.
PMID: 36912696
PMC: 10629783.
DOI: 10.1093/rheumatology/kead103.
2023 Taiwan Society of Cardiology (TSOC) and Taiwan College of Rheumatology (TCR) Joint Consensus on Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
Huang W, Hsieh S, Wu Y, Hsieh T, Wu Y, Li K
Acta Cardiol Sin. 2023; 39(2):213-241.
PMID: 36911549
PMC: 9999177.
DOI: 10.6515/ACS.202303_39(2).20230117A.
Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia.
Anderson J, Lau E
JACC Asia. 2023; 2(5):538-546.
PMID: 36624795
PMC: 9823284.
DOI: 10.1016/j.jacasi.2022.04.008.
The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
Xiang W, Dong R, Li M, Liu B, Ma Z, Yang Q
J Clin Med. 2023; 12(1).
PMID: 36614817
PMC: 9821587.
DOI: 10.3390/jcm12010013.
2020 Chinese Expert-based Consensus on the Diagnosis and Treatment of Connective Tissue Disease Associated Pulmonary Arterial Hypertension.
Zhao J, Wang Q, Wang Q, Zhang Y, Zhang N, Zhang R
Rheumatol Immunol Res. 2022; 2(2):63-78.
PMID: 36465975
PMC: 9524783.
DOI: 10.2478/rir-2021-0010.
Risk assessment in systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.
Wang Q, Qian J, Li M, Zhang X, Wei W, Zuo X
Ther Adv Chronic Dis. 2022; 13:20406223221112528.
PMID: 35898921
PMC: 9310292.
DOI: 10.1177/20406223221112528.